Defining severe shigellosis in the Enterics for Global Health study: A comparison of leading diarrhea severity definitions among children with *Shigella* diarrhea

Authors: Olivia Lang Schultes[1*], Aneeta Hotwani[2*], Patricia B. Pavlinac[1*], M. Jahangir Hossain[3*], Dilruba Nasrin[4*], Richard Omore[5*], Farhana Khanam[6*], Flywell Kawonga[7,8,9*], Paul F. Garcia Bardales[10*], Hannah E. Atlas[1], Alex O. Awuor[5], Henry Badji[3], Bakary Conteh[3], Jennifer Cornick[7,11], Erika L. Feutz[1], Sean R. Galagan[1], Ensa Gitteh[3], Eric R. Houpt[12], Junaid Iqbal[2], Sadia Islam[6], Furqan Kabir[6], Adama Mamby Keita[13], Jie Liu[14], Donnie Mategula[7,15,16], Chimwemwe Mhango[7,8,9,] Md Parvej Mosharraf[6], Billy Ogwel[5], Caleb Okonji[5], Uduma Uma Onwuchekwa[13], S.M. Azadul Alam Raz[6], Lucero Romaina-Cachique[10], Francesca Schiaffino[12,17], Tackeshy Pinedo Vasquez[10], Mohammad Tahir Yousafzai[2], Milagritos D. Tapia[4], Sharon M. Tennant[4,18] , Khuzwayo C. Jere[7,8,9δ], Margaret N. Kosek[12δ], Samba O. Sow[13δ], James A. Platts-Mills[12δ], Farah Naz Qamar[2δ], Elizabeth T. Rogawski McQuade[19δ], Karen L. Kotloff[4δ], John Benjamin Ochieng[5δ], Firdausi Qadri[6δ] on behalf of the EFGH Consortium[#]

Author Affiliations:

1. Department of Global Health, University of Washington, Seattle, Washington, USA
2. Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan
3. Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia
4. Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
5. Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya
6. International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
7. Malawi Liverpool Wellcome Trust Research Programme, Blantyre, Malawi
8. Institute of Infection, Veterinary & Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
9. Department of Medical Laboratory Sciences, School of Life Sciences and Allied Health Professions, Kamuzu University of Health Sciences, Blantyre, Malawi
10. Asociacion Benefica Prisma, Iquitos, Loreto, Peru
11. Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
12. Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA
13. Center for Vaccine Development Mali, Bamako, Mali
14. School of Public Health, Qingdao University, Qingdao, Shandong, China
15. Liverpool School of Tropical Medicine, Liverpool, United Kingdom
16. Kamuzu University of Health Sciences, Blantyre, Malawi
17. Facultad de Medicina Veterinaria y Zootecnia, Universidad Peruana Cayetano Heredia, Lima, Peru
18. Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
19. Department of Epidemiology, Emory University, Atlanta, Georgia, USA

Author Notes

[*]OS, AH, PP, MH, DN, RO, FKh, FKa, PGB, contributed equally as first authors

[δ]KJ, MK, SS, JPM, FQ, ERM, KK, JO, and FQ contributed equally as senior authors

Author Contributions

OLS, AH, PP, MJH, DN, RO, FKh, FKa, PGB, KCJ, MNK, SOS, JAPM, FNQ, ETRM, KLK, JBO, and FQ conceptualized the manuscript and contributed to writing and editing. OLS conducted the statistical analysis following the statistical analysis plan developed by the EFGH consortium. The EFGH protocol was co-developed by members of the EFGH consortium. All authors reviewed and approved the final manuscript.

Enterics for Global Health Study (EFGH) Consortium Contributions

[#]This study was conducted as part of the Enterics for Global Health (EFGH) consortium, a multi-country partnership that co-developed a standardized protocol and surveillance methods, built robust data infrastructure, and prioritized equitable authorship and capacity strengthening through inclusive governance, early-career researcher training, and country-led scientific leadership.

Enterics for Global Health Study (EFGH) Consortium Byline

Laura Riziki Aluoch, Lilian Achieng Ambila, Raphael Anyango, Evans Apondi, Md Taufiqur Rahman Bhuiyan, Bubacarr E. Ceesay, Nigel A. Cunliffe, Irum Fatima, Bri'Anna Horne, Md Ismail Hossen, Md Taufiqul Islam, Musa Jallow, Samba Juma Jallow, Jane Juma, Mehrab Karim, Youssouf Keita, Zubair Latif, Clement Lefu, Rebecca Maguire, Katia Manzanares Villanueva, Christine J. McGrath, Stephen Munga, Maureen Ndalama, Latif Ndeketa, Maribel Paredes Olortegui, Pablo Penatoro Yori, Syed Qudrat-E-Khuda, Md Nazmul Hasan Rajib, Queen Saidi, Doh Sanogo, Ousman Secka, Wagner Valentino Shapiama Lopez, Kirkby D. Tickell, Moussa Traore, Desiree Witte, Loyda Fiorella Zegarra Paredes

40-word summary

We compared six diarrhea severity definitions among children 6-35 months with *Shigella*. Moderate-to-severe diarrhea as measured by Modified Vesikari Score (MVS), MVS +/- dysentery, and MAL-ED score was associated with reduced length/height-for-age z-score and hospitalization or mortality.

Corresponding author: Olivia Schultes, oschul@uw.edu, 3980 15th Ave NE, Seattle, WA 98105

Abstract

Background: *Shigella* has high global burden and serious long-term outcomes among young children. Increasing antibiotic resistance makes *Shigella* vaccine development a critical priority. Choosing the optimal clinical efficacy endpoint for *Shigella* vaccine trials requires comparing existing diarrhea severity definitions among children with *Shigella*.

Methods: Six- to 35-month-old children presenting to a clinic with diarrhea were enrolled in Bangladesh, Kenya, Malawi, Mali, Pakistan, Peru, and The Gambia. Among children with *Shigella*, six dichotomized diarrhea severity definitions (GEMS moderate-to-severe diarrhea (MSD), Modified Vesikari Score (MVS), MVS +/- dysentery , Clark score, MAL-ED score, and *Shigella* mortality score) were examined against two outcomes: change in length/height-for-age z-score (ΔLAZ/HAZ) from enrollment to three-month follow-up and death or hospitalization within fourteen days of enrollment. We compared the performance of each severity score to predict outcomes using linear regression, measures of diagnostic accuracy, and Receiver Operating Characteristic (ROC) curves.

Results: Among 1,968 children with *Shigella*, moderate or severe diarrhea was negatively associated with ΔLAZ/HAZ by three definitions: MVS (-0.07 z-score, 95% CI -0.10 to -0.03), MVS +/- dysentery (-0.05, 95% CI -0.09 to -0.02), and MAL-ED score (-0.04, 95% CI -0.07 to 0.00). GEMS MSD (93.6%), MAL-ED (87.2%), MVS +/- dysentery (85.1%), and MVS (80.9%) had high sensitivity in predicting death or hospitalization, while *Shigella* mortality had the largest area under the curve (91.0).

Conclusions: MVS, MVS +/- dysentery, and the MAL-ED score identified adverse outcomes following *Shigella* diarrhea, indicating that they are viable options for a *Shigella* vaccine trial case definition.

Background

Shigella is a major cause of diarrhea among young children[1] causing approximately 60,000 deaths annually in children under five[2]. *Shigella* diarrhea also leads to an estimated 2 million cases of moderate-to-severe childhood stunting annually, and deaths caused by stunting increase the mortality burden of acute *Shigella* infections by 28%[2]. High disease burden, serious long-term consequences, and increasing resistance to common antibiotics support the need for making the development of *Shigella* vaccines an urgent global priority.

Several O-antigen vaccines targeting the most common *Shigella* serotypes (*S. flexneri* 1b, 2a, 3a, and 6, and *S. sonnei*) are under development[3–5]. Phase III licensure trials require a validated definition of clinical severity for the primary endpoint. Most licensed vaccines have demonstrated higher efficacy against more severe disease, including vaccines for rotavirus[6], cholera[7], dengue[8], and influenza[9], where licensure decisions were based on the demonstration of efficacy against more severe clinical presentation. This is expected to be true for *Shigella* as well; a human challenge study of the monovalent biconjugate *Shigella* vaccine, *Flexyn2a,* found 30% efficacy against mild disease and 72% efficacy against severe shigellosis[10]. From a public health and health system cost perspective, prevention of more severe disease is also a high priority.

Several diarrhea severity definitions could be proposed for a vaccine trial. The Global Enteric Multicenter Study moderate-to-severe diarrhea[1] (GEMS MSD) definition identified children in low- and middle-income countries (LMICs) with significantly higher frequency of episode-related death and stunting[1]. The *Shigella* mortality score was developed to distinguish children with *Shigella*-attributable MSD at high/low risk of death[11]. The modified Vesikari score (MVS) accounts for characteristics over the complete diarrhea episode[12] and predicts hospitalization among diarrhea cases[13]. The combination of MVS and visible blood in stools has also been posed as a severity-defining tool[14]. The Clark and MAL-ED scores are quantitative measures of diarrhea severity and were associated with hospitalization in the context of all-cause diarrhea in a community setting[15].

Choosing the optimal clinical severity definition for efficacy endpoints to be used in *Shigella* vaccine trials requires a head-to-head comparison of existing definitions in children with *Shigella*-attributable medically-attended diarrhea (MAD). With detailed clinical data, the use of both culture and quantitative real-time PCR (qPCR) for laboratory confirmation of *Shigella*, a large sample size[5,16,17], and longitudinal follow-up, the Enterics for Global Health (EFGH) study enabled a comprehensive evaluation of six diarrhea severity definitions. We established how well severity definitions predict *Shigella*-specific adverse outcomes such as linear growth faltering, hospitalization, and death-outcomes that a *Shigella* vaccine will aim to avert.

Methods

The EFGH *Shigella* surveillance study took place at clinical sites in Bangladesh, Kenya, Malawi, Mali, Pakistan, Peru, and The Gambia and aimed to establish incidence rates of *Shigella* diarrhea[5]. We enrolled children aged 6-35 months presenting to healthcare facilities with diarrhea and followed them for three months. Recruitment and follow up occurred between June 2022 and December 2024. Clinical research forms and other study documentation were prepared centrally and approved by local institutional review boards prior to enrollment[5].

At enrollment, caregivers reported the child's symptoms since episode onset and clinicians assessed temperature, signs of dehydration, and behavior[16]. Caregivers were given a paper diarrhea diary with visual cues and were trained to record daily information on the number of loose stools, dysentery, vomiting, and temperature for the following fourteen days. At week four and month three follow-up visits, caregivers returned the diary and answered questions about symptoms during the index episode since enrollment. Hospitalization information was abstracted from records and caregiver recall at follow-up visits, and deaths were identified through caregiver report at follow-up visits (methods Appendix). Trained study staff measured participant weight and length/height at enrollment and follow-up visits, with refresher trainings and standardization tests conducted every six months[16].

Three rectal swabs were taken at enrollment and were placed in a dry cryovial tube for qPCR testing, modified-buffer glycerol saline (mBGS), and Cary-Blair media, respectively. Participants were classified as having *Shigella*-attributable MAD if *Shigella* was identified via culture in either media type or by qPCR with a cycle threshold less than 29.5[17,18]. Whole stool was also collected and tested using qPCR in Bangladesh and The Gambia, and qPCR results from whole stool (using a cycle threshold cutoff of 29.8[17]) were used if rectal swab results were unavailable (n=194). Staff training and data quality plans ensured high data quality[19].

Among participants who returned the diarrhea diary (n=9,032, 95.3%), a record of all four severity indicators was complete for 90.9% of participants. Severity indicators were constructed using data from the diarrhea diary, enrollment, and follow-up visits; all children had information from at least one source for each severity indicator. Length/Height-for-age z-scores (LAZ/HAZ) were derived per World Health Organization guidelines[20], and the difference from enrollment to the three-month follow-up visit (ΔLAZ/HAZ) was calculated for each participant with both measurements. LAZ/HAZ scores <–6 or >6 were considered implausible and excluded[21], as were length/height increases of >6 cm or losses of > 1.5cm from enrollment to three-month follow-up.

Severity indicator (dehydration, duration ≥6 days, dysentery, fever, and vomiting) frequencies are presented among *Shigella*-attributable MAD and all MAD. We classified each child according to the following severity definitions: MVS[12], moderate or severe diarrhea by MVS or dysentery (MVS +/- dysentery)[14], GEMS MSD[1], *Shigella* mortality score[11], Clark score[22], and MAL-ED score[15] (methods Appendix, Table A1). The distribution of severity definition categories (mild vs. moderate or severe) was presented among *Shigella*-attributable MAD overall and by site, age group, and culture positivity.

Among *Shigella*-attributable MAD and all MAD, we estimated the association between each dichotomized severity score and the continuous outcome of ΔLAZ/HAZ using linear regression. Models were stratified by receipt of guideline-recommended antibiotics for shigellosis[23] (azithromycin, ciprofloxacin, ceftriaxone, or pivmecillinam) since treatment may affect the relationship between shigellosis severity and adverse outcomes[24]. Generalized estimating equations using robust standard errors were used to account for clustering of children who were enrolled for more than one diarrhea episode, and models were adjusted for enrollment LAZ/HAZ, site, and days from enrollment to three-month follow-up visit.

We determined the diagnostic accuracy of each dichotomized score in predicting hospitalization or death within fourteen days of enrollment, separately among *Shigella*-attributable MAD and all MAD

and stratified by antibiotic treatment. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated. We calculated bootstrapped 95% confidence intervals (95% CIs) for each measure stratified by site and clustered by unique child. We performed Receiver Operating Characteristics (ROC) analysis to compare the performance of continuous severity scores on predicting the outcome of hospitalization or mortality among children with *Shigella*-attributable MAD.

Analyses were conducted using R Statistical Software (v4.3; R Core Team 2024).

Results

Among 1,968 children with *Shigella*-attributable MAD, 48.6% were female, 19.6% were aged 6-11 months, 55.0% were 12-23 months, and 25.5% were 24-35 months (Table 1). Overall, 21.2% of children had moderate or severe wasting at enrollment, 28.0% were stunted, and 28.0% were moderately or severely underweight. Diarrhea severity indicators varied across sites. The proportion of children with some or severe dehydration was high in Peru (85.9%) and Kenya (56.6%), but under 20% in other sites. When examining dehydration signs across sites, child's condition (irritable/lethargic) was the most reported sign (40.3%), followed by ability to drink (thirsty/unable to drink, 25.5%), sunken eyes (17.6%), and slow/very slow skin pinch (11.9%). Similar patterns were observed among all children with MAD (Table A2).

Compared to all MAD, episodes of *Shigella*-attributable MAD had higher frequency of dysentery (27.9% versus 13.0%), longer duration (27.8% versus 35.8%), similar frequency of fever (68.8% versus 67.2%), and lower frequency of vomiting (37.1% versus 44.3%) and dehydration (23.4% versus 24.7%) (Figure A1). There was a higher proportion of episodes classified as moderate to severe among *Shigella*-attributable MAD compared to all MAD for all severity definitions except MVS (Table A3). Of the 1,968 children with *Shigella*-attributable MAD, 1,040 (52.8%) received guideline-recommended antibiotics.

Among *Shigella*-attributable MAD cases, the *Shigella* mortality score classified the smallest percentage of cases as moderate or severe (12.8%) while MVS +/- dysentery and MAL-ED classified the highest percentage of cases (54.3% and 53.6%, respectively). There was variation by site. Across severity definitions, children with *Shigella*-attributable MAD in Malawi and Mali had lower frequency of moderate or severe disease, whereas frequency was highest in Peru (Figure 1). A slightly higher proportion of younger children and culture-positive children (Figure A2) were classified as having moderate or severe *Shigella*-attributable MAD across severity definitions, most prominently among the definitions that include dysentery (MVS +/- dysentery and GEMS MSD).

Among children with *Shigella*-attributable MAD, moderate or severe diarrhea was significantly associated with ΔLAZ/HAZ from enrollment to three-month follow-up by three severity definitions (Figure 2). Children with moderate or severe *Shigella* by MVS had an estimated ΔLAZ/HAZ that was 0.07 z-scores lower (95% CI -0.10 to -0.03) compared to children with mild MVS, while children with more severe diarrhea by MVS +/- dysentery and MAL-ED scoring also were associated with reduced ΔLAZ/HAZ of -0.05 (95% CI -0.09 to -0.02) and -0.04 (95% CI -0.07 to 0.00), respectively. For these three definitions, the magnitude of the association was larger among children with *Shigella* who did not receive guideline-recommended antibiotics, with estimated reduction in ΔLAZ/HAZ of -0.10 (95% CI -0.15 to -0.05) for severe episodes by MVS, -0.10 (95% CI -0.15 to -0.05) by MVS +/- dysentery, and

-0.05 (95% CI -0.10 to 0.00) by the MAL-ED score. Similar associations were observed among all participants with MAD (Table A4).

Among children with *Shigella*-attributable MAD, there was one death (<0.1%) and 46 hospitalizations (2.3%) within 14 days of enrollment. The sensitivity of dichotomized severity definitions to predict hospitalization or mortality varied from 66.0% (Clark score and *Shigella* mortality score) to 93.6% (GEMS MSD) (Figure 3). The MAL-ED score (47.3%) had the lowest specificity, while the *Shigella* mortality score had the highest specificity (88.5%). When subset to children with *Shigella*-attributable MAD who did not receive guideline-recommended antibiotics, GEMS MSD and the MAL-ED score had the highest sensitivity for predicting hospitalization or mortality (90.9% and 90.9%, respectively), while the *Shigella* mortality score had the highest specificity (87.6%). Sensitivity and specificity among all MAD were similar to those among *Shigella*-attributable MAD (Table A5).

We calculated ROC curves among *Shigella*-attributable MAD for the four numeric scores. *Shigella* mortality had the largest area under the curve ([AUC] 91.0, 95% CI 86.0 to 94.9), while MVS (79.4, 95% CI 73.4 to 85.1), Clark (76.7, 95% CI 70.3 to 83.2), and MAL-ED (75.8, 95% CI 69.7 to 82.0) had similar AUCs (Figure 4). In separate sensitivity analyses, we removed hospitalization and dehydration, from the severity definitions when present (Figure A3). Without hospitalization the *Shigella* mortality score had a smaller AUC (61.7, 95% CI 54.1 to 69.9), while MVS (73.7, 95% CI 66.8 to 80.2), Clark (76.8, 95% CI 70.3 to 83.2), and MAL-ED (75.8, 95% CI 69.7 to 82.0) had AUCs similar to the original scores. Without dehydration, each of the scores performed similarly to the original scores, with AUCs of 94.6 (95% CI 89.5 to 98.1), 79.1 (95% CI 73.4 to 84.3), 76.8 (95% CI 70.3 to 83.2), and 73.9 (95% CI 67.3 to 80.5) for *Shigella* mortality, MVS, Clark, and MAL-ED, respectively.

Conclusions

We evaluated the ability of six diarrhea severity definitions to disaggregate children with and without more severe *Shigella*-attributable MAD. *Shigella*-attributable MAD was more severe than overall MAD, underscoring its clinical and public health relevance and providing motivation for a *Shigella* vaccine. The proportion of *Shigella*-attributable MAD classified as moderate or severe varied across definitions, which has implications for vaccine trial sample sizes. Moderate or severe *Shigella*-attributable MAD identified using three of the six definitions—MVS, MVS +/- dysentery, and MAL-ED—was significantly associated with ΔLAZ/HAZ. Finally, most severity definitions demonstrated high sensitivity in predicting hospitalization or death, important clinical outcomes that vaccine candidates aim to prevent.

An ideal severity definition for *Shigella* vaccine trials identifies the vaccine-preventable subset of *Shigella* cases, which is often the more severe cases of disease[6,25]. The *Shigella* mortality score classified the fewest children as having moderate or severe diarrhea in our study, followed by Clark, however these two definitions did not outperform other definitions. MVS +/- dysentery and the MAL-ED score were more inclusive definitions that also performed well at predicting hospitalization, death, and linear growth loss.

Children with *Shigella*-attributable MAD had a higher proportion of moderate or severe diarrhea than all MAD by every severity definition except MVS. Fever, vomiting, dehydration, longer duration of illness, and more than six stools per 24 hours were common among children with *Shigella*-attributable MAD, all features likely to be important in classifying severe shigellosis beyond dysentery

alone. Efforts to differentiate *Shigella* from other etiologies[26,27], such as viral etiologies, have found vomiting to be less common among children with *Shigella*. However, we identified vomiting in >30% of *Shigella*-attributable MAD cases, making it a viable feature to include in a severity definition among children with shigellosis. Children with culture-confirmed *Shigella* had more severe diarrhea by definitions that include dysentery compared to qPCR-attributable but culture negative cases. Culture confirmed *Shigella* cases were more likely to present with dysentery than qPCR-attributable cases[11], which may reflect the timing of disease progression identified by qPCR versus culture or the pathogen load required for detection by culture.

The considerable variation in severity classification by site was at least partially driven by differences in some or severe dehydration. Despite concerns that the components of the dehydration classification are subjective[28], no single component drove site differences in frequency of dehydration and the removal of dehydration did not substantially change the ability of severity definitions to predict hospitalization or mortality. Variation in severity by site could be due to differences in age distribution of cases, prevalent serotypes, and care-seeking behaviors[29,30]. For instance, in Peru, *Shigella* was more prevalent among the youngest age group, which tends to present with more severe disease[11]. Measuring dehydration is complex and future work may consider collecting data on alternative measures of dehydration such as the DHAKA score, which was found to better predict percent dehydration[28].

Because *Shigella* is frequently implicated in linear growth faltering, the precursor to stunting, the ideal clinical endpoint for severe shigellosis would include children at risk for *Shigella*-induced growth faltering. We found that severity as measured by MVS, MVS +/- dysentery, and the MAL-ED score was significantly associated with linear growth faltering, irrespective of antibiotic use, while severity measured by the *Shigella* mortality score, GEMS MSD, and Clark score showed non-significant associations of lesser magnitude. The three scores with significant associations included diarrhea duration as a component, a well-known risk factor for stunting[31]. This suggests that the severity definition used in a vaccine trial should at least include a component related to diarrhea duration to capture the *Shigella* infections most likely to lead to growth faltering.

We considered the composite outcome of hospitalization or mortality within 14 days of enrollment due to the small number of deaths among *Shigella*-attributable MAD cases (n=1) and because previous research has found hospitalization to be both a proxy for mortality[11] and associated with health care system costs[32]. Acknowledging there are severe cases of *Shigella* that do not lead to hospitalization or death, we focused on sensitivity when comparing definitions and found that four definitions demonstrated high sensitivity in predicting hospitalization or death: GEMS MSD, MVS, MVS +/- dysentery, and MAL-ED. To address the challenge of hospitalization being present in several severity definitions, we performed a sensitivity analysis in ROC curves removing hospitalization as a component in the four definitions where it is included. The modified versions of MVS and MVS +/- dysentery performed similarly to the original definitions, whereas the modified version of the two definitions where hospitalization was heavily weighted (GEMS MSD and *Shigella* mortality score) did not perform as well. MVS, MVS +/- dysentery, and the MAL-ED score were the most sensitive scores in predicting hospitalization and mortality and the most robust to the removal of hospitalization. Previous research found that MVS and the MAL-ED score were associated with hospitalization among children enrolled at an emergency department[13] and in the community[15], respectively, and our

207 study now builds upon these findings to suggest that these scores may be useful proxies for
208 hospitalization or death among *Shigella* cases in LMICs.

209 This large, multi-site study utilized detailed clinical data to compare diarrhea severity definitions
210 among children with *Shigella* across diverse settings. Given the three-month follow-up period, we
211 examined hospitalization, mortality, and growth faltering as these are the most serious measured
212 outcomes that a vaccine may avert but acknowledge that the shorter follow-up time may have limited
213 our ability to fully assess growth faltering. In addition, the overlap between severity definitions and
214 the outcome of hospitalization or mortality limited our ability to comprehensively evaluate the two
215 definitions where hospitalization was weighted heavily, GEMS MSD and *Shigella* mortality score. The
216 magnitude of linear growth faltering observed in this study may not be clinically meaningful on an
217 individual level but is similar in magnitude to highly referenced findings in the *Shigella* growth
218 literature[24]. Finally, antibiotic treatment is likely to be contributing to the relationship between
219 severity and clinical outcomes, although our analyses stratifying by appropriate antibiotic treatment
220 attempted to overcome this.

221 We saw similar performance across three severity definitions (MVS, MVS +/- dysentery, and the MAL-
222 ED score) examining two types of adverse outcomes from *Shigella*. Of these definitions, only MVS +/-
223 dysentery contains dysentery, a clear marker of *Shigella* clinical severity that should be included in a
224 vaccine trial case definition. Diarrhea duration has been previously linked with mortality[11] and may
225 improve prediction of changes in LAZ/HAZ, indicating it should be considered in the severity
226 definition used for eventual *Shigella* vaccine trials. Other practical considerations in severity
227 definition selection include the trade-offs between simpler definitions, which are easy to understand
228 and may only require data collection at one point in time, versus scores, which can be further
229 disaggregated but may require follow-up data collection[14]. There are multiple viable existing
230 options for a moderate or severe *Shigella* case definition that balance association with relevant
231 adverse outcomes with requisite underlying frequency in populations of interest.

Acknowledgements

The authors thank the children who participated in these studies and their families, and the dedicated physicians, nurses, scientists, and staff at each study site for their dedication and outstanding performance of clinical and laboratory study activities.

Conflicts of interest

No reported conflicts.

Data Sharing

The EFGH statistical analysis plan (https://clinicaltrials.gov/study/NCT06047821) and study protocol (https://academic.oup.com/ofid/issue/11/Supplement_1) were made publicly available. The datasets were deidentified and anonymized and will be publicly available upon publication of the manuscript.

Funding source

Bill & Melinda Gates Foundation (award numbers INV-028721, INV-041730, INV-016650, INV-031791, INV-036891, INV-036892)

References

1. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. The Lancet **2013**; 382:209–222.

2. Anderson JD, Bagamian KH, Muhib F, et al. Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis. Lancet Glob Health **2019**; 7:e321–e330.

3. Passwell JH, Ashkenzi S, Banet-Levi Y, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine **2010**; 28:2231–2235.

4. MacLennan CA, Grow S, Ma L-F, Steele AD. The Shigella Vaccines Pipeline. Vaccines (Basel) **2022**; 10.

5. Vannice K, MacLennan CA, Long J, Steele AD. Optimizing Vaccine Trials for Enteric Diseases: The Enterics for Global Health (EFGH) Shigella Surveillance Study. Open Forum Infect Dis **2024**; 11:S1–S5.

6. Tapia MD, Armah G, Breiman RF, et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine **2012**; 30.

7. Khanam F, Islam MT, Ahmmed F, et al. Evaluation of oral cholera vaccine (Euvichol-Plus) effectiveness against Vibrio cholerae in Bangladesh: an interim analysis. BMJ Glob Health **2025**; 10.

8. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. New England Journal of Medicine **2015**; 373:1195–1206.

9. Dbaibo G, Amanullah A, Claeys C, et al. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions during Five Influenza Seasons: A Randomized Clinical Trial. Pediatric Infectious Disease Journal **2020**; 39:E1–E10.

10. Talaat KR, Alaimo C, Martin P, et al. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection. EBioMedicine **2021**; 66.

11. Pavlinac PB, Platts-Mills JA, Tickell KD, et al. The Clinical Presentation of Culture-positive and Culture-negative, Quantitative Polymerase Chain Reaction (qPCR)-Attributable Shigellosis in the Global Enteric Multicenter Study and Derivation of a Shigella Severity Score: Implications for Pediatric Shigella Vaccine Trials. Clinical Infectious Diseases **2021**; 73:E569–E579.

12. Ruuska T, Vesikari T. Rotavirus disease in finnish children: Use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis **1990**; 22:259–267.

13. Schnadower D, Tarr PI, Gorelick MH, et al. Validation of the modified vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr **2013**; 57:514–519.

14. Pavlinac PB, Rogawski McQuade ET, Platts-Mills JA, et al. Pivotal Shigella Vaccine Efficacy Trials-Study Design Considerations from a Shigella Vaccine Trial Design Working Group. Vaccines (Basel) **2022**; 10.

15. Lee GO, Richard SA, Kang G, et al. A comparison of diarrheal severity scores in the MAL-ED multisite community-based cohort study. J Pediatr Gastroenterol Nutr **2016**; 63:466–473.

16. Atlas HE, Conteh B, Islam MT, et al. Diarrhea Case Surveillance in the Enterics for Global Health Shigella Surveillance Study: Epidemiologic Methods. Open Forum Infect Dis **2024**; 11:S6–S16.

17. Liu J, Garcia Bardales PF, Islam K, et al. Shigella Detection and Molecular Serotyping With a Customized TaqMan Array Card in the Enterics for Global Health (EFGH): Shigella Surveillance Study. Open Forum Infect Dis **2024**; 11:S34–S40.

18. Horne B, Badji H, Bhuiyan MTR, et al. Microbiological Methods Used in the Enterics for Global Health Shigella Surveillance Study. Open Forum Infect Dis **2024**; 11:S25–S33.

19. Feutz E, Biswas PK, Ndeketa L, et al. Data Management in Multicountry Consortium Studies: The Enterics For Global Health (EFGH) Shigella Surveillance Study Example. Open Forum Infect Dis **2024**; 11:S48–S57.

20. Organization WH. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. World Health Organization, 2006. Available at: https://iris.who.int/handle/10665/43413. Accessed 7 April 2025.

21. Blössner M, Siyam A, Borghi E, et al. WHO Anthro for Personal Computers Manual: Software for assessing growth and development of the world's children. https://cdn.who.int/media/docs/default-source/child-growth/child-growth-standards/software/anthro-pc-manual-v322.pdf?sfvrsn=c4e76522_2. 2010; Available at: https://cdn.who.int/media/docs/default-source/child-growth/child-growth-standards/software/anthro-pc-manual-v322.pdf?sfvrsn=c4e76522_2. Accessed 7 April 2025.

22. Fired Clark H, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. Journal of Infectious Diseases **1988**; 158:570–587.

23. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005. Available at: https://iris.who.int/bitstream/handle/10665/43252/924159330X.pdf?sequence=1. Accessed 8 April 2025.

24. Nasrin D, Blackwelder WC, Sommerfelt H, et al. Pathogens Associated With Linear Growth Faltering in Children With Diarrhea and Impact of Antibiotic Treatment: The Global Enteric Multicenter Study. Journal of Infectious Diseases **2021**; 224:S848–S855.

25. Vesikari T, Matson DO, Dennehy P, et al. Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine. New England Journal of Medicine **2006**; 354:23–33.

26. Kotloff KL, Platts-Mills JA, Nasrin D, Roose A, Blackwelder WC, Levine MM. Global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques. Vaccine **2017**; 35:6783–6789.

27. Platts-Mills JA, Liu J, Rogawski ET, et al. Use of quantitative molecular diagnostic methods to assess the aetiology, burden, and clinical characteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL-ED cohort study. Lancet Glob Health **2018**; 6:e1309–e1318.

28. Levine AC, Glavis-Bloom J, Modi P, et al. External validation of the DHAKA score and comparison with the current IMCI algorithm for the assessment of dehydration in children with diarrhoea: a prospective cohort study. Lancet Glob Health **2016**; 4:e744–e751.

29. Kasumba IN, Badji H, Powell H, et al. Shigella in Africa: New Insights from the Vaccine Impact on Diarrhea in Africa (VIDA) Study. Clinical Infectious Diseases **2023**; 76:S66–S76.

30. Sreeramareddy CT, Low YP, Forsberg BC. Slow progress in diarrhea case management in low and middle income countries: Evidence from cross-sectional national surveys, 1985-2012. BMC Pediatr **2017**; 17.

31. Checkley W, Buckley G, Gilman RH, et al. Multi-country analysis of the effects of diarrhoea on childhood stunting. Int J Epidemiol **2008**; 37:816–830.

32. Riewpaiboon A, Youngkong S, Sreshthaputra N, et al. A cost function analysis of shigellosis in Thailand. In: Value in Health. Blackwell Publishing Inc., 2008.

33. Integrated Management of Childhood Illness Chart Booklet. WHO, 2014.

Table 1. Demographic characteristics and diarrhea severity indicators of participants with *Shigella*-attributable diarrhea by site.

Characteristic	**Bangladesh** N = 388	**Kenya** N = 175	**Malawi** N = 173	**Mali** N = 240	**Pakistan** N = 368	**Peru** N = 227	**The Gambia** N = 397	**Overall** N = 1,968
Demographics								
Age (months), n (%)								
6-11	92 (23.7)	24 (13.7)	25 (14.5)	39 (16.3)	91 (24.7)	61 (26.9)	53 (13.4)	385 (19.6)
12-23	197 (50.8)	97 (55.4)	88 (50.9)	156 (65.0)	195 (53.0)	115 (50.7)	234 (58.9)	1,082 (55.0)
24-35	99 (25.5)	54 (30.9)	60 (34.7)	45 (18.8)	82 (22.3)	51 (22.5)	110 (27.7)	501 (25.5)
Female, n (%)	179 (46.1)	90 (51.4)	78 (45.1)	119 (49.6)	190 (51.6)	108 (47.6)	192 (48.4)	956 (48.6)
Mother completed secondary school or greater, n (%)	114 (29.4)	55 (31.4)	24 (13.9)	20 (8.4)	89 (24.2)	111 (48.9)	8 (2.0)	421 (21.4)
Wealth index, n (%)[1]								
Quintile 1 (fewest assets)	0 (0.0)	2 (1.1)	22 (12.7)	3 (1.3)	107 (29.1)	105 (46.3)	100 (25.2)	339 (17.2)
Quintile 2	22 (5.7)	36 (20.6)	48 (27.7)	68 (28.3)	126 (34.2)	87 (38.3)	178 (44.8)	565 (28.7)
Quintile 3	84 (21.6)	53 (30.3)	78 (45.1)	114 (47.5)	70 (19.0)	34 (15.0)	92 (23.2)	525 (26.7)
Quintile 4	127 (32.7)	62 (35.4)	20 (11.6)	54 (22.5)	45 (12.2)	1 (0.4)	27 (6.8)	336 (17.1)
Quintile 5 (most assets)	155 (39.9)	22 (12.6)	5 (2.9)	1 (0.4)	20 (5.4)	0 (0.0)	0 (0.0)	203 (10.3)
Received age-appropriate rotavirus vaccination, n (%)[2]	-	121 (80.7)	96 (100.0)	191 (97.9)	228 (85.7)	169 (88.9)	384 (98.2)	1,189 (92.3)
Wasting, n (%)[3]								
None	321 (82.7)	166 (94.9)	160 (93.0)	187 (77.9)	230 (63.4)	211 (95.0)	268 (67.5)	1,543 (78.8)
Moderate	52 (13.4)	7 (4.0)	10 (5.8)	43 (17.9)	92 (25.3)	10 (4.5)	105 (26.4)	319 (16.3)
Severe	15 (3.9)	2 (1.1)	2 (1.2)	10 (4.2)	41 (11.3)	1 (0.5)	24 (6.0)	95 (4.9)
Stunted, n (%)[4]	112 (28.9)	37 (21.1)	61 (35.5)	41 (17.1)	152 (41.9)	53 (23.9)	92 (23.2)	548 (28.0)
Underweight, n (%)[5]								
None	294 (75.8)	161 (92.0)	149 (86.1)	184 (76.7)	187 (51.0)	202 (89.0)	240 (60.5)	1,417 (72.0)
Moderate	76 (19.6)	11 (6.3)	19 (11.0)	40 (16.7)	112 (30.5)	18 (7.9)	119 (30.0)	395 (20.1)
Severe	18 (4.6)	3 (1.7)	5 (2.9)	16 (6.7)	68 (18.5)	7 (3.1)	38 (9.6)	155 (7.9)
Diarrhea episode severity indicators								
Diarrhea episode ≥ 6 days, n (%)	240 (61.9)	43 (24.6)	31 (17.9)	51 (21.3)	195 (53.0)	95 (41.9)	49 (12.3)	704 (35.8)

Characteristic	Bangladesh N = 388	Kenya N = 175	Malawi N = 173	Mali N = 240	Pakistan N = 368	Peru N = 227	The Gambia N = 397	Overall N = 1,968
Number of days of diarrhea, Median (IQR)	6 (5, 9)	3 (2, 5)	3 (2, 5)	4 (3, 5)	6 (4, 9)	5 (3, 7)	3 (2, 5)	4 (3, 7)
Maximum number of stool in one day, Median (IQR)	9 (7, 12)	5 (4, 6)	7 (5, 8)	5 (4, 6)	7 (6, 10)	5 (4, 8)	6 (5, 7)	6 (5, 8)
Dysentery, n (%)	129 (33.2)	42 (24.0)	29 (16.8)	32 (13.3)	115 (31.3)	62 (27.3)	140 (35.3)	549 (27.9)
Dehydration, n (%)[6]								
None	353 (91.0)	76 (43.4)	167 (96.5)	207 (86.3)	303 (82.3)	32 (14.1)	369 (92.9)	1,507 (76.6)
Some	35 (9.0)	95 (54.3)	6 (3.5)	31 (12.9)	62 (16.8)	193 (85.0)	23 (5.8)	445 (22.6)
Severe	0 (0.0)	4 (2.3)	0 (0.0)	2 (0.8)	3 (0.8)	2 (0.9)	5 (1.3)	16 (0.8)
Rehydrated at facility, n (%)	386 (99.5)	175 (100.0)	173 (100.0)	239 (99.6)	363 (98.6)	214 (94.3)	394 (99.2)	1,944 (98.8)
Any fever during episode, n (%)	217 (55.9)	146 (83.4)	109 (63.0)	122 (50.8)	238 (64.7)	176 (77.5)	346 (87.2)	1,354 (68.8)
Fever duration in days, Median (IQR)	1 (0, 3)	2 (1, 3)	1 (0, 2)	0 (0, 2)	1 (0, 4)	1 (0, 3)	2 (1, 4)	2 (0, 3)
Maximum axillary temperature, Median (IQR)	36.9 (36.5, 37.3)	37.2 (36.7, 37.9)	36.7 (36.2, 37.1)	36.7 (36.3, 37.2)	36.6 (36.2, 37.0)	36.8 (36.7, 37.5)	37.1 (36.7, 37.8)	36.8 (36.5, 37.4)
Confirmed temperature, Median (IQR)	36.8 (36.4, 37.2)	37.0 (36.7, 37.8)	36.4 (36.1, 36.8)	36.7 (36.3, 37.2)	36.5 (36.2, 37.0)	36.8 (36.6, 37.4)	37.1 (36.7, 37.8)	36.8 (36.4, 37.3)
Any vomiting during episode, n (%)	133 (34.3)	81 (46.3)	67 (38.7)	59 (24.6)	130 (35.3)	121 (53.3)	140 (35.3)	731 (37.1)
Vomiting duration in days, Median (IQR)	0 (0, 2)	0 (0, 2)	0 (0, 1)	0 (0, 0)	0 (0, 1)	1 (0, 1)	0 (0, 1)	0 (0, 1)
Maximum number of times vomiting in one day, Median (IQR)	0 (0, 2)	0 (0, 2)	0 (0, 1)	0 (0, 0)	0 (0, 1)	1 (0, 3)	0 (0, 2)	0 (0, 2)
Clark score behavioral signs, n (%)								
None	40 (10.3)	51 (29.1)	161 (93.1)	220 (91.7)	260 (70.7)	60 (26.4)	379 (95.5)	1,171 (59.5)
Irritable	347 (89.4)	122 (69.7)	8 (4.6)	20 (8.3)	105 (28.5)	165 (72.7)	14 (3.5)	781 (39.7)
Lethargic/Unconscious	1 (0.3)	2 (1.1)	0 (0.0)	0 (0.0)	3 (0.8)	1 (0.4)	4 (1.0)	11 (0.6)
Convulsions	0 (0.0)	0 (0.0)	4 (2.3)	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	5 (0.3)
Dehydration signs[7]								
Child condition, n (%)								
Well/Alert	40 (10.3)	51 (29.1)	165 (95.4)	220 (91.7)	260 (70.7)	60 (26.4)	379 (95.5)	1,175 (59.7)
Restless/Irritable	347 (89.4)	122 (69.7)	8 (4.6)	20 (8.3)	105 (28.5)	166 (73.1)	14 (3.5)	782 (39.7)
Lethargic or Unconscious	1 (0.3)	2 (1.1)	0 (0.0)	0 (0.0)	3 (0.8)	1 (0.4)	4 (1.0)	11 (0.6)

Characteristic	Bangladesh N = 388	Kenya N = 175	Malawi N = 173	Mali N = 240	Pakistan N = 368	Peru N = 227	The Gambia N = 397	Overall N = 1,968
Sunken eyes, n (%)	0 (0.0)	49 (28.0)	6 (3.5)	38 (15.8)	55 (14.9)	167 (73.6)	32 (8.1)	347 (17.6)
Ability to drink, n (%)								
Normal/Not Thirsty	352 (90.7)	87 (49.7)	168 (97.1)	138 (57.5)	301 (81.8)	46 (20.3)	375 (94.5)	1,467 (74.5)
Drinks eagerly/Thirsty	36 (9.3)	86 (49.1)	5 (2.9)	101 (42.1)	65 (17.7)	181 (79.7)	20 (5.0)	494 (25.1)
Drinks poorly/Unable to drink	0 (0.0)	2 (1.1)	0 (0.0)	1 (0.4)	2 (0.5)	0 (0.0)	2 (0.5)	7 (0.4)
Skin pinch, n (%)								
Immediately	374 (96.4)	144 (82.3)	164 (94.8)	227 (94.6)	345 (94.0)	108 (47.6)	370 (93.2)	1,732 (88.1)
1 to <2 seconds (slowly)	14 (3.6)	29 (16.6)	8 (4.6)	11 (4.6)	22 (6.0)	118 (52.0)	23 (5.8)	225 (11.4)
2+ seconds (very slowly)	0 (0.0)	2 (1.1)	1 (0.6)	2 (0.8)	0 (0.0)	1 (0.4)	4 (1.0)	10 (0.5)

[1] Wealth index quintile calculated from country-specific wealth assessments derived from Demographic Health Surveys as detailed in Chakraborty, GHSP, 2016.
[2] Defined as having received all age-appropriate doses of rotavirus vaccination according to national vaccination schedules, allowing a one month buffer. Note that rotavirus is not included in the Bangladesh childhood vaccine schedule.
[3] Moderate wasting defined as a weight-for-height z-score of < -2 or a mid-upper arm circumference of <12.5 cm and severe wasting defined as a weight-for-height z-score of < -3 or a mid-upper arm circumference of <11.5 cm.
[4] Stunting defined as a height-for-age z-score of < -2.
[5] Moderate underweight defined as a weight-for-age z-score of < -2 and severe underweight defined as a weight-for-age z-score of < -3.
[6] Defined according to World Health Organization Integrated Management of Childhood Illness (WHO IMCI).
[7] Components of WHO IMCI dehydration definition.



Figure 1. Severity of *Shigella*-attributable medically attended diarrhea by severity definition and site. Percentages indicate moderate to severe diarrhea.

GEMS: Global Enteric Multicenter Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score
Scores dichotomized as follows: MVS dichotomized as mild (<9 points) vs. moderate or severe (≥9 points); MVS +/- dysentery dichotomized as mild with no dysentery vs. moderate/severe or dysentery; GEMS MSD dichotomized as less-severe-diarrhea vs. moderate-to-severe-diarrhea; *Shigella* mortality score dichotomized as mild (<6 points) vs. moderate or severe (≥6 points) diarrhea; Clark score dichotomized as mild (<9 points) vs. moderate to severe diarrhea (≥9 points); MAL-ED dichotomized as non-severe (<6 points) vs. severe diarrhea (≥6 points)

Alt text: Bar graph depicting the percentage of *Shigella*-attributable medically attended diarrhea classified as moderate or severe by each severity definition by site.



Figure 2. Association between more severe diarrhea by dichotomized severity definitions and change in length/ height-for-age z-score (ΔLAZ/HAZ) from enrollment to 3-month follow-up among *Shigella*-attributable medically attended diarrhea, overall and stratified by guideline-recommended antibiotic treatment. Models adjusted for baseline LAZ/HAZ, site, and number of days from enrollment to 3-month follow-up visit.

GEMS: Global Enteric Multicenter Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score
Scores dichotomized as follows: MVS dichotomized as mild (<9 points) vs. moderate or severe (≥9 points); MVS +/- dysentery dichotomized as mild with no dysentery vs. moderate/severe or dysentery; GEMS MSD dichotomized as less-severe-diarrhea vs. moderate-to-severe-diarrhea; *Shigella* mortality score dichotomized as mild (<6 points) vs. moderate or severe (≥6 points) diarrhea; Clark score dichotomized as mild (<9 points) vs. moderate to severe diarrhea (≥9 points); MAL-ED dichotomized as non-severe (<6 points) vs. severe diarrhea (≥6 points)

Alt text: Forest plot depicting the association between each dichotomized severity definition and change in length/height-for-age z-score from enrollment to three-month follow-up among all *Shigella*-attributable medically attended diarrhea cases and stratified by receipt of guideline-recommended antibiotics. Among all *Shigella* cases, MVS, MVS +/- dysentery, and the MAL-ED score are negatively associated with change in length/height-for-age z-score.



Figure 3. Sensitivity and specificity of dichotomized diarrhea severity scores in identifying hospitalization and/or mortality within 14 days of enrollment among *Shigella*-attributable medically-attended diarrhea. Calculated among all diarrhea cases and stratified by guideline-recommended antibiotic treatment.

GEMS: Global Enteric Multicenter Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score
Scores dichotomized as follows: MVS dichotomized as mild (<9 points) vs. moderate or severe (≥9 points); MVS +/- dysentery dichotomized as mild with no dysentery vs. moderate/severe or dysentery; GEMS MSD dichotomized as less-severe-diarrhea vs. moderate-to-severe-diarrhea; *Shigella* mortality score dichotomized as mild (<6 points) vs. moderate or severe (≥6 points) diarrhea; Clark score dichotomized as mild (<9 points) vs. moderate to severe diarrhea (≥9 points); MAL-ED dichotomized as non-severe (<6 points) vs. severe diarrhea (≥6 points)

Alt text: Two side-by-site forest plots showing the sensitivity and specificity, respectively, of each dichotomized severity definition in predicting hospitalization or mortality within 14 days of enrollment. Estimates calculated among all *Shigella*-attributable medically attended diarrhea cases and stratified by receipt of guideline-recommended antibiotics. GEMS MSD, MAL-ED, MVS, and MVS +/- dysentery have the highest sensitivity, while *Shigella* mortality score and Clark score have the highest specificity.



Figure 4. Receiver operating characteristic (ROC) curves of four continuous severity scores on the outcome of hospitalization or mortality within 14 days of enrollment among children with *Shigella*-attributable medically-attended diarrhea. Shaded bands represent 95% confidence intervals. Plotted points represent sensitivity and specificity of threshold used for dichotomizing four continuous scores, as well as sensitivity and specificity of two non-numeric severity definitions.

GEMS: Global Enteric Multicenter Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score Scores dichotomized as follows: MVS dichotomized as mild (<9 points) vs. moderate or severe (≥9 points); MVS +/- dysentery dichotomized as mild with no dysentery vs. moderate/severe or dysentery; GEMS MSD dichotomized as less-severe-diarrhea vs. moderate-to-severe-diarrhea; *Shigella* mortality score dichotomized as mild (<6 points) vs. moderate or severe (≥6 points) diarrhea; Clark score dichotomized as mild (<9 points) vs. moderate to severe diarrhea (≥9 points); MAL-ED dichotomized as non-severe (<6 points) vs. severe diarrhea (≥6 points)

Alt text: Receiver operating characteristic curves of four continuous severity scores on hospitalization or mortality within 14 days of enrollment among children with *Shigella*-attributable medically-attended diarrhea. *Shigella* mortality score has the highest area under the curve, and the other three severity scores (MVS, Clark score, and MAL-ED score) have similar curves with overlapping confidence interval bands.

Methods appendix

Key definitions

Diarrhea episode: The diarrhea episode was defined as the period from diarrhea start to the last day of diarrhea followed by two diarrhea-free days. The first day of the index diarrhea episode was identified by caregivers during the screening process. The last day of the episode was determined using the diarrhea diary and follow-up visits, when caregivers were asked about the last day of the participant's episode. The number of loose stools was recorded daily in the diarrhea diary, and the last day of the episode was determined by the last day with at least three recorded loose stools, followed by two days of less than three loose stools. When the diarrhea episode was still ongoing at the end of the diarrhea diary (14 days after enrollment), the last date of the diarrhea episode reported at the follow-up visit was used. If the last date reported at follow-up was missing or prior to 14 days after enrollment, then the episode was assumed to have ended on the last day of the diarrhea diary. In cases where the diarrhea diary was incomplete, any days with missing values for loose stool count were assumed to have less than three loose stools. When no diarrhea diary was submitted, the diarrhea end date reported by caregivers at the follow-up visit was used. If both the diarrhea diary and follow-up date were missing, the diarrhea episode was assumed to end on the day of enrollment.

Number of days of diarrhea: The number of days of diarrhea was defined as the number of days within the diarrhea episode where the caregiver reported three or more loose stools.

Diarrhea duration prior to presentation: The number of days from diarrhea episode start to enrollment date (including the day of enrollment).

Maximum number of loose stools per day: At enrollment and follow-up visits, caregivers are asked to report the maximum number of loose stools their child has passed in a single day during the index episode. The number of loose stools per day from enrollment to the end of the episode is also recorded in the diarrhea diary. The maximum number of loose stools in a 24-hour period is taken from the maximum of these three sources.

Dysentery: Caregivers were asked to report if they observed blood in the participant's stool at any point during the index diarrhea episode at screening, enrollment, and follow-up visits. Caregivers also recorded the presence of blood in stool daily for 14 days following enrollment in the diarrhea diary. Additionally, clinician diagnosis of dysentery was recorded at enrollment, both at presentation and discharge from the health facility. If responses from caregivers or clinician diagnosis at any time point indicated that the child had blood in stool during the index episode, the child was classified as having dysentery.

Dehydration: All participants were classified as having none, some, or severe dehydration at enrollment using World Health Organization (WHO) dehydration categories from the Integrated Management of Childhood Illness guidelines[33]. A child with two or more of the following symptoms was classified as having severe dehydration: lethargic or unconscious, abnormally sunken eyes observed by clinician and confirmed by caregiver, child drinks poorly or is unable to drink, and skin pinch returns to normal after 2 or more seconds. A child who does not meet the criteria for severely dehydrated and has two or more of the following symptoms was classified as having some

dehydration: restless or irritable, abnormally sunken eyes observed by clinician and confirmed by caregiver, child drinks eagerly or is thirsty, and skin pinch returns to normal in 1 to 2 seconds. A child who does not meet the criteria for either some or severe dehydration is classified as having none.

Rehydration treatment: A participant was considered to have received rehydration treatment at enrollment if they received oral rehydration solution or IV rehydration at the health facility or if they were instructed to continue oral rehydration treatment at home upon discharge.

Maximum axillary or rectal temperature: Temperature was measured by clinicians at enrollment. Caregivers with a thermometer at home were instructed to take and record their child's temperature in the diarrhea diary daily from enrollment through 14 days after enrollment. At the follow-up visit, caregivers were asked to report the highest temperature recorded during the diarrhea episode if the child had been feverish. Temperatures taken via armpit, forehead, or unknown location were classified as axillary temperatures. Oral temperature was converted to axillary by subtracting 0.5°C, and rectal temperature was converted to axillary temperature using the following formula: axillary temperature = 0.94 * rectal temperature + 2.92. The maximum axillary temperature was calculated for each child by taking the highest recorded temperature from any source during the diarrhea episode. This was used to calculate the maximum rectal temperature using the above formula.

Confirmed temperature: Confirmed temperature was the temperature taken at enrollment by a clinician.

Duration of fever: At enrollment, caregivers are asked how many days the child has felt hot to the touch since the beginning of the diarrhea episode. Following enrollment, temperature data is recorded via the diarrhea diary and follow-up visits. For each day in the diarrhea diary, the child is considered feverish if they have an oral temperature of ≥37.8°C or an axillary temperature of ≥37.2°C or, if temperature is not measured, if the caregiver records that the child feels "hot to touch". If no temperature is taken and the caregiver does not record a "hot to touch" indication, the child is assumed to not have fever for that day. Separately from the diarrhea diary, caregivers are asked during follow-up visits how many days the child had a fever from enrollment until the end of the index diarrhea episode. The number of days a participant has fever from enrollment until the end of the episode is taken from the diarrhea diary except when the diarrhea diary is missing or when the follow-up response indicates more feverish days than the diarrhea diary. In those cases, the number of days indicated by caregiver's follow-up response is used. The number of days of fever or hot to touch assessment for the entire diarrhea episode is calculated by adding the number of days reported at enrollment to the number of days calculated by either the diary or follow-up visits.

Maximum number of times vomiting in a day: Caregivers reported the maximum number of times the child vomited in a day since the beginning of the diarrhea at enrollment. Caregivers then recorded the number of times their child vomited daily from enrollment through 14 days after enrollment in the diarrhea diary. At the follow-up visit, caregivers were asked to report the maximum number of times the child vomited in a day from enrollment until the end of the episode. If the diarrhea diary was returned, the maximum number of times vomited in a day was the highest recorded value from the enrollment and diarrhea diary during the diarrhea episode. If no diarrhea diary was returned, then the maximum number of times vomited in a day was the highest recorded value from the enrollment and follow-up responses.

Duration vomiting: At enrollment, caregivers are asked how many days the child has vomited since the beginning of the diarrhea episode. The number of days reported at enrollment is summed with the number of days the child has vomiting during the episode as indicated in the diarrhea diary. When data in the diary is missing, it is assumed no vomiting occurred that day.

Behavioral signs: Behavioral signs are categorized based on clinician assessment at enrollment. A clinician report of a child experiencing convulsions were classified as having "Seizures"; here, we used convulsions as a proxy for seizures. Children who were not experiencing convulsions and were reported to be lethargic or unconscious were classified as "Lethargic/Listless", and those who were not experiencing convulsions and were reported to be restless or irritable were classified as "Irritable/Less playful".

Guideline-recommended antibiotics: Children who received azithromycin, ciprofloxacin, ceftriaxone, or pivmecillinam during the diarrhea episode were classified as having received guideline-recommended antibiotics, based on WHO recommendations for *Shigella* treatment[23]. All other children were classified as having not received guideline-recommended antibiotics.

Hospitalization was assessed at enrollment and follow-up visits by caregiver recall and hospital records (gold standard) when available. Date and time of admission, length of hospital stay, presenting signs/symptoms, and treatment received were obtained when available. Hospitalization was defined as an overnight stay (child was on the ward from at least 12am to 6am or self-discharged prior to that timeframe). Hospitalizations missing admission date (n=7) were excluded from analysis.

Deaths occurring within the three-month follow-up period were assessed by caregiver report at each scheduled visit or during upcoming visit phone reminders. Date and cause of death were obtained from caregiver history, hospital records or death certificate, when available. The death certificate was considered the gold standard for date of death.

Length/Height-for-age z-score (LAZ/HAZ): The LAZ/HAZ was calculated for each child at enrollment, 4-week follow-up visit, and 3-month follow-up visit according to WHO guidelines[20]. Length (<24 months of age) or height (≥24 months of age) was measured during each visit to the nearest 0.1 cm[16]. The average of two measurements was used, and if the first two measurements had a difference of >0.5 cm a third measurement was taken. Each study team received initial training and conducted anthropometry standardization tests every 6 months, which guided subsequent refresher trainings. At least 5% of children at each site were re-measured by a gold standard measurer for quality control.

Severity definitions

Modified Vesikari Score (MVS)[12]**:** The MVS is a summed score with the following components: number of days of diarrhea of 1-4 days is 1 point, 5 days is 2 points, and ≥6 days is 3 points; a maximum of 1-3 loose stools in a 24-hour period is 1 point, 4-5 loose stools is 2 points, and ≥6 loose stools is 3 points; duration of vomiting of 1 day is 1 point, 2 days is 2 points, and ≥3 days is 3 points; a maximum of 1 vomiting episode in a 24-hour period is 1 point, 2-4 episodes is 2 points, and ≥5 episodes is 3 points; a maximum axillary temperature of 36.6-37.9°C is 1 point, 38.0-38.4°C is 2 points, and ≥38.5°C is 3 points; some dehydration at enrollment is 2 points and severe dehydration

at enrollment is 3 points; and rehydration treatment is 1 point and hospitalization is 2 points. The scores will be summed and categorized as mild illness (0-8 points), moderate illness (9-10 points), and severe illness (11+ points).

Moderate to severe MVS +/- dysentery[14]**:** Moderate or severe diarrhea by MVS or dysentery will be defined as a MVS of 9 or more points or presence of dysentery, defined as above. Participants with an MVS score of 8 or less who do not have dysentery will be classified as mild with no dysentery.

GEMS moderate-to-severe diarrhea (MSD)[1]**:** GEMS MSD is defined as presenting to a health facility with diarrhea and at least one of the following: some or severe dehydration by WHO IMCI criteria, dysentery, or inpatient admission. Less-severe-diarrhea (LSD) is defined as presenting to a health facility for diarrhea without MSD.

***Shigella* mortality score**[11]**:** *Shigella* mortality score is a summed score with the following components: duration of diarrhea episode of 1-3 days is 0 points, 4-5 days is 2 points, and ≥6 days is 3 points; WHO-defined dehydration classification of some dehydration at enrollment is 4 points, and severe dehydration at enrollment is 8 points; and inpatient admission is 5 points. The scores will be summed and categorized as mild (<6 points), moderate (6-8 points), and severe (9+ points).

Clark score[22]**:** Clark score is a summed score with the following components: number of days of diarrhea of 1-4 days is 1 point, 5-7 days is 2 points, and >7 days is 3 points; a maximum of 2-4 loose stools in a 24-hour period is 1 point, 5-7 loose stools is 2 points, and >7 loose stools is 3 points; duration of vomiting of 2 days is 1 point, 3-5 days is 2 points, and >5 days is 3 points; a maximum of 1-3 vomiting episodes in a 24-hour period is 1 point, 4-6 episodes is 2 points, and >6 is 3 points; duration of reported fever of 1-2 days is 1 point, 3-4 days is 2 points, and ≥5 days is 3 points; a maximum rectal temperature of 38-38.2°C is 1 point, 38.3-38.7°C is 2 points, and ≥38.8°C is 3 points; clinician behavioral classification of irritable/less playful is 1 point, lethargic/listless is 2 points, and seizures is 3 points. The scores will be summed and categorized as mild (2-8 points) and moderate to severe (9+ points).

MAL-ED score[15]**:** MAL-ED score is a summed score with the following components: number of days of diarrhea of 2-4 days is 1 point, 5-7 days is 2 points, and ≥8 days is 3 points; a maximum of <5 loose stools in a 24-hour period is 1 point, 5-7 loose stools is 2 points, and ≥8 stools is 3 points; duration of vomiting of 1 day is 1 point, 2 days is 2 points, and ≥3 days is 3 points; duration of reported fever of ≥1 days is 1 point; clinician confirmed temperature of ≥37.5°C is 2 points; WHO-defined dehydration classification of some dehydration at enrollment is 2 points, and severe dehydration at enrollment is 3 points. The scores will be summed and categorized as non-severe (<6 points) or severe (6+ points)

<u>Reformulating severity definitions for sensitivity analysis</u>

To further explore the relationship between severity definitions and the combined outcome of hospitalization or death, we performed two sensitivity analysis removing hospitalization and dehydration, respectively, from definitions which included either as a component of the definition and then rescaling scores. Four definitions include hospitalization (MVS, MVS +/- dysentery, GEMS-MSD, and the *Shigella* mortality score) and five include dehydration (MVS, MVS +/- dysentery, GEMS-

MSD, the *Shigella* mortality score, and the MAL-ED score). For GEMS-MSD, hospitalization or dehydration were dropped as a criterion for moderate-to-severe diarrhea. For the four numeric scores, hospitalization or dehydration was removed from the score calculations, and a new threshold for moderate to severe disease was calculated as the same proportion of points from the original threshold to the original highest possible severity score. For MVS and MVS +/- dysentery, the treatment and dehydration components were removed, reducing the highest possible score from 20 to 18 and 17 and the threshold for moderate or severe disease from 9 to 8 and 8 points, respectively. For the *Shigella* mortality score, removing hospitalization reduced the highest possible score from 16 to 11 and the threshold for moderate or severe disease from 6 to 4 points, while removing dehydration reduced the highest possible score to 8 and the threshold for moderate or severe disease to 3 points. For the MAL-ED score, removing dehydration reduced the highest possible score from 15 to 12 and changed the threshold for moderate or severe disease from 6 to 5 points.

Results appendix

Table A1: Construction of severity definitions.

Severity definitions		GEMS-MSD	MVS	MVS +/- dysentery	Clark	MAL-ED	*Shigella* mortality
		No criteria present = less-severe diarrhea Any criteria present = moderate-to-severe diarrhea (MSD)	Total Score: 0-8 = Mild 9-10 = Moderate ≥11 = Severe	MVS score of <9 and no dysentery = Mild with no dysentery MVS score of ≥9 or dysentery = Moderate/severe or dysentery	Total Score: 2-8 = Mild ≥9 = Moderate to severe	Total Score: <6 = Non-severe ≥6 = Severe	Total Score: <6 = Mild 6-8 = Moderate ≥9 = Severe
Severity indicator	**Description of severity indicator**						
Number of days of diarrhea	Number of days with diarrhea (3 or more loose stools) within the diarrhea episode		1-4 days = 1 5 days = 2 ≥6 days = 3	1-4 days = 1 5 days = 2 ≥6 days = 3	1-4 days = 1 5-7 days = 2 >7 days = 3	2-4 days = 1 5-7 days = 2 ≥8 days = 3	
Diarrhea duration prior to presentation	Number of days from diarrhea episode start to enrollment date (including day of enrollment)						1-3 days = 0 4-5 days = 2 ≥6 days = 3
Dysentery	Blood in stool reported by caregiver or clinician	Dysentery = MSD		Dysentery = Moderate/severe or dysentery			
Treatment	Rehydration: Oral rehydration solution (ORS) or IV rehydration given at enrollment Hospitalization: Participant received inpatient care from 12am-6am during the diarrhea episode	Hospitalization = MSD	Rehydration = 1 Hospitalization = 2	Rehydration = 1 Hospitalization = 2			Hospitalization = 5
Maximum number of loose stools	Maximum number of loose stools reported by caregiver in one day during diarrhea episode		1-3 stools = 1 4-5 stools = 2 ≥6 stools = 3	1-3 stools = 1 4-5 stools = 2 ≥6 stools = 3	2-4 stools = 1 5-7 stools = 2 >7 stools = 3	<5 stools = 1 5-7 stools = 2 ≥8 stools = 3	
Maximum number of times vomited	Maximum number of times vomiting reported by caregiver in one day during diarrhea episode		1 time = 1 2-4 times = 2 ≥5 times = 3	1 time = 1 2-4 times = 2 ≥5 times = 3	1-3 times = 1 4-6 times = 2 >6 times = 3		
Dehydration	Classified as none, some, or severe following WHO integrated management of childhood illness (IMCI) guidance	Some = MSD Severe = MSD	None = 0 Some = 2 Severe = 3	None = 0 Some = 2 Severe = 3		Some = 2 Severe = 3	None = 0 Some = 4 Severe = 8

Vomiting duration	Number of days of vomiting reported by caregiver during diarrhea episode	1 day = 1 2 days = 2 ≥3 days = 3	1 day = 1 2 days = 2 ≥3 days = 3	2 days = 1 3-5 days = 2 >5 days = 3	1 day = 1 2 days = 2 ≥3 days = 3
Duration of fever	Number of days of fever or hot-to-touch reported by caregiver during diarrhea episode			1-2 days = 1 3-4 days = 2 ≥5 days = 3	≥1 day = 1
Maximum axillary temperature	Maximum axillary temperature measured at enrollment or reported by caregiver during diarrhea episode	36.6-37.9 = 1 38.0-38.4 = 2 ≥38.5 = 3	36.6-37.9 = 1 38.0-38.4 = 2 ≥38.5 = 3		
Maximum rectal temperature	Maximum rectal temperature measured at enrollment or reported by caregiver during diarrhea episode			38.0-38.2 = 1 38.3-38.7 = 2 ≥38.8 = 3	
Confirmed Temperature	Temperature taken by clinician at enrollment				≥37.5 = 2
Behavioral Signs	Assessed by clinician at enrollment			Irritable = 1 Lethargic = 2 Seizures = 3	

Table A2. Demographic characteristics and diarrhea severity indicators of participants with medically-attended diarrhea (all participants) by site.

Characteristic	**Bangladesh** N = 1,361	**Kenya** N = 1,400	**Malawi** N = 1,399	**Mali** N = 1,400	**Pakistan** N = 1,400	**Peru** N = 1,117	**The Gambia** N = 1,399	**Overall** N = 9,476
Demographics								
Age (months), n (%)								
6-11	572 (42.0)	560 (40.0)	478 (34.2)	600 (42.9)	454 (32.4)	365 (32.7)	446 (31.9)	3,475 (36.7)
12-23	588 (43.2)	595 (42.5)	627 (44.8)	613 (43.8)	646 (46.1)	585 (52.4)	718 (51.3)	4,372 (46.1)
24-35	201 (14.8)	245 (17.5)	294 (21.0)	187 (13.4)	300 (21.4)	167 (15.0)	235 (16.8)	1,629 (17.2)
Female, n (%)	596 (43.8)	637 (45.5)	651 (46.5)	643 (45.9)	655 (46.8)	488 (43.7)	646 (46.2)	4,316 (45.5)
Mother completed secondary school or greater, n (%)	400 (29.4)	404 (28.9)	221 (15.8)	125 (9.0)	286 (20.4)	608 (54.4)	58 (4.2)	2,102 (22.2)
Wealth index, n (%)[1]								
Quintile 1 (fewest assets)	0 (0.0)	34 (2.4)	158 (11.3)	23 (1.6)	458 (32.7)	507 (45.4)	346 (24.7)	1,526 (16.1)
Quintile 2	83 (6.1)	247 (17.6)	449 (32.1)	430 (30.7)	475 (33.9)	430 (38.5)	596 (42.6)	2,710 (28.6)
Quintile 3	278 (20.4)	404 (28.9)	538 (38.5)	600 (42.9)	235 (16.8)	173 (15.5)	355 (25.4)	2,583 (27.3)
Quintile 4	430 (31.6)	522 (37.3)	196 (14.0)	335 (23.9)	170 (12.1)	7 (0.6)	102 (7.3)	1,762 (18.6)
Quintile 5 (most assets)	570 (41.9)	193 (13.8)	58 (4.1)	12 (0.9)	62 (4.4)	0 (0.0)	0 (0.0)	895 (9.4)
Received age-appropriate rotavirus vaccination, n (%)[2]	-	814 (67.2)	919 (96.3)	1,168 (95.0)	845 (85.3)	858 (90.7)	1,364 (98.3)	5,968 (88.8)
Wasting, n (%)[3]								
None	1,119 (82.3)	1,337 (95.7)	1,327 (95.4)	1,086 (77.6)	913 (65.8)	1,052 (95.5)	1,000 (71.7)	7,834 (83.1)
Moderate	206 (15.1)	48 (3.4)	53 (3.8)	261 (18.6)	334 (24.1)	44 (4.0)	307 (22.0)	1,253 (13.3)
Severe	35 (2.6)	12 (0.9)	11 (0.8)	53 (3.8)	141 (10.2)	6 (0.5)	87 (6.2)	345 (3.7)
Stunted, n (%)[4]	331 (24.3)	257 (18.4)	402 (28.9)	183 (13.1)	540 (39.0)	233 (21.2)	288 (20.7)	2,234 (23.7)
Underweight, n (%)[5]								
None	1,081 (79.4)	1,297 (92.6)	1,224 (87.5)	1,088 (77.7)	799 (57.2)	1,008 (90.2)	919 (65.7)	7,416 (78.3)
Moderate	222 (16.3)	82 (5.9)	139 (9.9)	239 (17.1)	370 (26.5)	90 (8.1)	351 (25.1)	1,493 (15.8)
Severe	58 (4.3)	21 (1.5)	36 (2.6)	73 (5.2)	227 (16.3)	19 (1.7)	129 (9.2)	563 (5.9)
Diarrhea episode severity indicators								
Diarrhea episode ≥ 6 days, n (%)	779 (57.2)	267 (19.1)	250 (17.9)	200 (14.3)	569 (40.6)	416 (37.2)	155 (11.1)	2,636 (27.8)

Characteristic	Bangladesh N = 1,361	Kenya N = 1,400	Malawi N = 1,399	Mali N = 1,400	Pakistan N = 1,400	Peru N = 1,117	The Gambia N = 1,399	Overall N = 9,476
Number of days of diarrhea, Median (IQR)	6 (4, 8)	3 (2, 5)	3 (3, 5)	4 (3, 5)	5 (3, 7)	5 (3, 7)	3 (2, 4)	4 (3, 6)
Maximum number of stool in one day, Median (IQR)	10 (7, 12)	5 (4, 6)	6 (5, 8)	5 (4, 6)	7 (6, 9)	5 (4, 7)	5 (4, 7)	6 (4, 8)
Dysentery, n (%)	206 (15.1)	148 (10.6)	138 (9.9)	93 (6.6)	234 (16.7)	170 (15.2)	241 (17.2)	1,230 (13.0)
Dehydration, n (%)[6]								
None	1,191 (87.5)	656 (46.9)	1,348 (96.4)	1,236 (88.3)	1,185 (84.6)	214 (19.2)	1,310 (93.6)	7,140 (75.3)
Some	168 (12.3)	685 (48.9)	49 (3.5)	154 (11.0)	207 (14.8)	897 (80.3)	70 (5.0)	2,230 (23.5)
Severe	2 (0.1)	59 (4.2)	2 (0.1)	10 (0.7)	8 (0.6)	6 (0.5)	19 (1.4)	106 (1.1)
Rehydrated at facility, n (%)	1,359 (99.9)	1,397 (99.8)	1,399 (100.0)	1,395 (99.6)	1,376 (98.3)	1,016 (91.0)	1,390 (99.4)	9,332 (98.5)
Any fever during episode, n (%)	776 (57.0)	1,167 (83.4)	880 (62.9)	720 (51.4)	849 (60.6)	743 (66.5)	1,231 (88.0)	6,366 (67.2)
Fever duration in days, Median (IQR)	1 (0, 3)	2 (1, 3)	1 (0, 2)	0 (0, 2)	1 (0, 3)	1 (0, 2)	2 (2, 4)	1 (0, 3)
Maximum axillary temperature, Median (IQR)	36.8 (36.5, 37.2)	37.2 (36.7, 37.9)	36.7 (36.3, 37.2)	36.7 (36.4, 37.2)	36.6 (36.2, 37.0)	36.8 (36.6, 37.3)	37.1 (36.7, 37.7)	36.8 (36.5, 37.4)
Confirmed temperature, Median (IQR)	36.7 (36.4, 37.1)	37.1 (36.7, 37.8)	36.4 (36.1, 36.8)	36.7 (36.4, 37.2)	36.6 (36.2, 37.0)	36.8 (36.6, 37.2)	37.1 (36.7, 37.7)	36.8 (36.4, 37.3)
Any vomiting during episode, n (%)	648 (47.6)	749 (53.5)	637 (45.5)	417 (29.8)	562 (40.1)	541 (48.4)	641 (45.8)	4,195 (44.3)
Vomiting duration in days, Median (IQR)	0 (0, 2)	1 (0, 2)	0 (0, 2)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 2)	0 (0, 2)
Maximum number of times vomiting in one day, Median (IQR)	0 (0, 3)	1 (0, 2)	0 (0, 2)	0 (0, 2)	0 (0, 2)	0 (0, 3)	0 (0, 3)	0 (0, 2)
Clark score behavioral signs, n (%)								
None	137 (10.1)	374 (26.7)	1,344 (96.1)	1,293 (92.4)	1,056 (75.4)	354 (31.7)	1,348 (96.4)	5,906 (62.3)
Irritable	1,221 (89.7)	999 (71.4)	30 (2.1)	105 (7.5)	331 (23.6)	755 (67.6)	35 (2.5)	3,476 (36.7)
Lethargic/Unconscious	3 (0.2)	20 (1.4)	1 (0.1)	1 (0.1)	13 (0.9)	5 (0.4)	14 (1.0)	57 (0.6)
Convulsions	0 (0.0)	7 (0.5)	24 (1.7)	1 (0.1)	0 (0.0)	3 (0.3)	2 (0.1)	37 (0.4)
Dehydration signs[7]								
Child condition, n (%)								
Well/Alert	137 (10.1)	375 (26.8)	1,367 (97.7)	1,294 (92.4)	1,056 (75.4)	354 (31.7)	1,350 (96.5)	5,933 (62.6)
Restless/Irritable	1,221 (89.7)	1,005 (71.8)	31 (2.2)	105 (7.5)	331 (23.6)	758 (67.9)	35 (2.5)	3,486 (36.8)

Characteristic	Bangladesh N = 1,361	Kenya N = 1,400	Malawi N = 1,399	Mali N = 1,400	Pakistan N = 1,400	Peru N = 1,117	The Gambia N = 1,399	Overall N = 9,476
Lethargic or Unconscious	3 (0.2)	20 (1.4)	1 (0.1)	1 (0.1)	13 (0.9)	5 (0.4)	14 (1.0)	57 (0.6)
Sunken eyes, n (%)	1 (0.1)	364 (26.0)	58 (4.1)	239 (17.1)	176 (12.6)	757 (67.8)	96 (6.9)	1,691 (17.8)
Ability to drink, n (%)								
Normal/Not Thirsty	1,195 (87.8)	750 (53.6)	1,336 (95.5)	842 (60.1)	1,134 (81.0)	248 (22.2)	1,327 (94.9)	6,832 (72.1)
Drinks eagerly/Thirsty	163 (12.0)	612 (43.7)	57 (4.1)	548 (39.1)	260 (18.6)	868 (77.7)	66 (4.7)	2,574 (27.2)
Drinks poorly/Unable to drink	3 (0.2)	38 (2.7)	6 (0.4)	10 (0.7)	6 (0.4)	1 (0.1)	6 (0.4)	70 (0.7)
Skin pinch, n (%)								
Immediately	1,279 (94.0)	1,196 (85.4)	1,357 (97.0)	1,329 (94.9)	1,336 (95.5)	623 (55.8)	1,317 (94.1)	8,437 (89.0)
1 to <2 seconds (slowly)	79 (5.8)	181 (12.9)	40 (2.9)	65 (4.6)	63 (4.5)	492 (44.0)	68 (4.9)	988 (10.4)
2+ seconds (very slowly)	3 (0.2)	23 (1.6)	2 (0.1)	6 (0.4)	0 (0.0)	2 (0.2)	14 (1.0)	50 (0.5)

[1] Wealth index quintile calculated from country-specific wealth assessments derived from Demographic Health Surveys as detailed in Chakraborty, GHSP, 2016.
[2] Defined as having received all age-appropriate doses of rotavirus vaccination according to national vaccination schedules, allowing a one month buffer. Note that rotavirus is not included in the Bangladesh childhood vaccine schedule.
[3] Moderate wasting defined as a weight-for-height z-score of < -2 or a mid-upper arm circumference of <12.5 cm and severe wasting defined as a weight-for-height z-score of < -3 or a mid-upper arm circumference of <11.5 cm.
[4] Stunting defined as a height-for-age z-score of < -2.
[5] Moderate underweight defined as a weight-for-age z-score of < -2 and severe underweight defined as a weight-for-age z-score of < -3.
[6] Defined according to World Health Organization Integrated Management of Childhood Illness (WHO IMCI).
[7] Components of WHO IMCI dehydration definition.

Table A3. Proportion of children with medically-attended diarrhea (MAD) and *Shigella*-attributable MAD by severity score categories by site.

Severity definition	Bangladesh	Kenya	Malawi	Mali	Pakistan	Peru	The Gambia	Overall
All MAD								
GEMS MSD, n (%)[1]								
Less-severe	966 (71.0)	584 (41.7)	1,214 (86.8)	1,161 (82.9)	989 (70.6)	184 (16.5)	1,062 (75.9)	6,160 (65.0)
Moderate-to-severe	395 (29.0)	816 (58.3)	185 (13.2)	239 (17.1)	411 (29.4)	933 (83.5)	337 (24.1)	3,316 (35.0)
Modified Vesikari score (MVS), Median (IQR), n (%)[2]	8 (7, 12)	9 (6, 11)	7 (5, 9)	6 (5, 9)	8 (6, 10)	9 (7, 11)	7 (6, 10)	8 (6, 10)
Mild	692 (50.8)	668 (47.7)	946 (67.6)	1,046 (74.7)	883 (63.1)	456 (40.8)	888 (63.5)	5,579 (58.9)
Moderate	175 (12.9)	289 (20.6)	235 (16.8)	173 (12.4)	239 (17.1)	294 (26.3)	248 (17.7)	1,653 (17.4)
Severe	494 (36.3)	443 (31.6)	218 (15.6)	181 (12.9)	278 (19.9)	367 (32.9)	263 (18.8)	2,244 (23.7)
Moderate or severe diarrhea by MVS or dysentery, n (%)[3]	796 (58.5)	802 (57.3)	538 (38.5)	407 (29.1)	644 (46.0)	722 (64.6)	673 (48.1)	4,582 (48.4)
Clark score, Median (IQR), n (%)[4]	8 (6, 11)	7 (5, 9)	5 (4, 7)	4 (3, 6)	6 (4, 9)	6 (4, 8)	6 (5, 8)	6 (4, 8)
Mild	770 (56.6)	971 (69.4)	1,176 (84.1)	1,264 (90.3)	1,033 (73.8)	853 (76.4)	1,077 (77.0)	7,144 (75.4)
Moderate to severe	591 (43.4)	429 (30.6)	223 (15.9)	136 (9.7)	367 (26.2)	264 (23.6)	322 (23.0)	2,332 (24.6)
MAL-ED score, Median (IQR), n (%)[5]	6 (5, 9)	6 (5, 8)	5 (4, 6)	4 (3, 6)	6 (4, 7)	7 (5, 8)	5 (4, 7)	6 (4, 7)
Non-Severe	493 (36.2)	511 (36.5)	877 (62.7)	973 (69.5)	666 (47.6)	328 (29.4)	713 (51.0)	4,561 (48.1)
Severe	868 (63.8)	889 (63.5)	522 (37.3)	427 (30.5)	734 (52.4)	789 (70.6)	686 (49.0)	4,915 (51.9)
Shigella mortality score, Median (IQR), n (%)[6]	2 (0, 3)	4 (0, 4)	0 (0, 0)	0 (0, 2)	2 (0, 2)	4 (4, 6)	0 (0, 0)	0 (0, 4)
Mild	1,221 (89.7)	1,174 (83.9)	1,393 (99.6)	1,343 (95.9)	1,273 (90.9)	585 (52.4)	1,351 (96.6)	8,340 (88.0)
Moderate	74 (5.4)	163 (11.6)	5 (0.4)	55 (3.9)	122 (8.7)	521 (46.6)	20 (1.4)	960 (10.1)
Severe	66 (4.8)	63 (4.5)	1 (0.1)	2 (0.1)	5 (0.4)	11 (1.0)	28 (2.0)	176 (1.9)
***Shigella*-attributable MAD**								
GEMS MSD, n (%)[1]								
Less-severe	226 (58.2)	60 (34.3)	138 (79.8)	182 (75.8)	213 (57.9)	24 (10.6)	235 (59.2)	1,078 (54.8)
Moderate-to-severe	162 (41.8)	115 (65.7)	35 (20.2)	58 (24.2)	155 (42.1)	203 (89.4)	162 (40.8)	890 (45.2)
Modified Vesikari score (MVS), Median (IQR), n (%)[2]	8 (7, 12)	9 (7, 11)	7 (5, 9)	6 (5, 8)	8 (6, 10)	10 (8, 12)	7 (6, 9)	8 (6, 10)
Mild	242 (62.4)	81 (46.3)	128 (74.0)	185 (77.1)	227 (61.7)	72 (31.7)	286 (72.0)	1,221 (62.0)
Moderate	41 (10.6)	45 (25.7)	26 (15.0)	24 (10.0)	73 (19.8)	62 (27.3)	45 (11.3)	316 (16.1)
Severe	105 (27.1)	49 (28.0)	19 (11.0)	31 (12.9)	68 (18.5)	93 (41.0)	66 (16.6)	431 (21.9)
Moderate or severe diarrhea by MVS or dysentery, n (%)[3]	226 (58.2)	116 (66.3)	63 (36.4)	76 (31.7)	199 (54.1)	174 (76.7)	215 (54.2)	1,069 (54.3)

Severity definition	Bangladesh	Kenya	Malawi	Mali	Pakistan	Peru	The Gambia	Overall
Clark score, Median (IQR), n (%)[4]	7 (6, 10)	7 (5, 9)	5 (4, 7)	4 (3, 6)	7 (5, 9)	7 (5, 9)	6 (4, 8)	6 (5, 9)
Mild	235 (60.6)	127 (72.6)	149 (86.1)	215 (89.6)	262 (71.2)	158 (69.6)	316 (79.6)	1,462 (74.3)
Moderate to severe	153 (39.4)	48 (27.4)	24 (13.9)	25 (10.4)	106 (28.8)	69 (30.4)	81 (20.4)	506 (25.7)
MAL-ED score, Median (IQR), n (%)[5]	6 (5, 9)	6 (5, 8)	5 (4, 6)	4 (3, 6)	6 (4, 8)	7 (6, 9)	5 (4, 7)	6 (4, 8)
Non-Severe	158 (40.7)	56 (32.0)	116 (67.1)	164 (68.3)	154 (41.8)	49 (21.6)	217 (54.7)	914 (46.4)
Severe	230 (59.3)	119 (68.0)	57 (32.9)	76 (31.7)	214 (58.2)	178 (78.4)	180 (45.3)	1,054 (53.6)
Shigella mortality score, Median (IQR), n (%)[6]	2 (0, 3)	4 (0, 4)	0 (0, 0)	0 (0, 2)	2 (0, 3)	6 (4, 6)	0 (0, 0)	2 (0, 3)
Mild	359 (92.5)	149 (85.1)	171 (98.8)	227 (94.6)	321 (87.2)	108 (47.6)	381 (96.0)	1,716 (87.2)
Moderate	20 (5.2)	20 (11.4)	1 (0.6)	11 (4.6)	45 (12.2)	116 (51.1)	7 (1.8)	220 (11.2)
Severe	9 (2.3)	6 (3.4)	1 (0.6)	2 (0.8)	2 (0.5)	3 (1.3)	9 (2.3)	32 (1.6)

GEMS: Global Enteric Multicenter Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score, WHO: World Health Organization.

[1] Defined as in Kotloff, Lancet GH, 2019. Moderate-to-severe diarrhea (MSD) defined as presenting to a health facility with diarrhea and severe or some dehydration (by WHO criteria), visible blood in stool, or inpatient admission. Less-severe-diarrhea defined as presenting to a health facility without MSD.

[2] Defined as in PATH Vesikari Clinical Severity Scoring System Manual: Duration of diarrhea: 1-4 days (1 point), 5 days (2 points) ≥6 days (3 points); Max # of stool in 24 hour period: 1-3 (1 point), 4-5 (2 points), ≥6 (3 points); Duration of vomiting: 1 day (1 point), 2 days (2 points), ≥3 days (3 points); max # of vomiting episodes in 24 hour period: 1 (1 point), 2-4 (2 points), ≥5 (3 points); Axillary temperature 36.6-37.9°C (1 point), 38.0-38.4°C (2 points), ≥38.5°C (3 points); dehydration 1-5% (2 points), ≥6% (3 points); treatment: rehydration (1 point), hospitalization (2 points). Classified as mild (0-8 points), moderate (9-10 points), and severe (≥11 points).

[3] Defined as in Pavlinac, Vaccines, 2022 as a MVS of 9+ or presence of visible blood in stool.

[4] Defined as in Clark, JID, 1988. Duration of diarrhea: 1-4 days (1 point), 5-7 days (2 points) >7 days (3 points); Max # of stool in 24 hour period: 2-4 (1 point), 5-7 (2 points), >7 (3 points); Duration of vomiting: 2 days (1 point), 3-5 days (2 points), >5 days (3 points); max # of vomiting episodes in 24 hour period: 1-3 (1 point), 4-6 (2 points), >6 (3 points); Duration of reported fever: 1-2 days (1 point), 3-4 days (2 points), ≥5 days (3 points); Rectal temperature 38-38.2°C (1 point), 38.3-38.7°C (2 points), ≥38.8°C (3 points); behavioral signs: Irritable/less playful (1 point), Lethargic/listless (2 points), Seizures (3 points). Classified as mild (2-8 points) and moderate to severe (≥9 points).

[5] Defined as in Lee, J Pediatr Gastroenterol Nutr., 2016: Duration of diarrhea: 2-4 days (1 point), 5-7 days (2 points), ≥8 days (3 points); Max # of stool in 24 hour period: <5 loose stools/24 hours (1 point), 5-7 loose stools/24 hours (2 points), ≥8 stools/24 hours (3 points); Duration of vomiting: 1 day (1 point), 2 days (2 points), ≥3 days (3 points); duration of reported fever: 1+ days (1 point); Confirmed temperature: ≥37.5°C (confirmed by field worker) (2 points); Dehydration: Some (2 points), severe (3 points). Classified as non-severe (0-5 points) and severe (≥6 points).

[6] Defined as in Pavlinac, CID, 2021. Duration of diarrhea through day of presentation: 1-3 days (0 points), 4-5 days (2 points), ≥6 days (3 points); WHO-defined dehydration categories: severe (8 points), some (4 points), none (0 points); inpatient admission (5 points). Classified as mild (0-5 points), moderate (6-8 points), and severe (≥9 points).



Figure A1. Frequency of severity indicators among all medically-attended diarrhea (MAD) and *Shigella*-attributable MAD. Percentages indicate presence of indicator.

Alt text: Bar graph depicting the percentage of children with five severity indicators (dehydration, duration ≥6 days, dysentery, fever, and vomiting) among all medically-attended diarrhea and *Shigella*-attributable medically attended diarrhea.



Figure A2. Percentage of children with *Shigella*-attributable medically attended diarrhea classified as having moderate to severe diarrhea by each severity definition by age group and culture positivity.

GEMS: Global Enteric Multicenter Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score
Scores dichotomized as follows: MVS dichotomized as mild (<9 points) vs. moderate or severe (≥9 points); MVS +/- dysentery dichotomized as mild with no dysentery vs. moderate/severe or dysentery; GEMS MSD dichotomized as less-severe-diarrhea vs. moderate-to-severe-diarrhea; *Shigella* mortality score dichotomized as mild (<6 points) vs. moderate or severe (≥6 points) diarrhea; Clark score dichotomized as mild (<9 points) vs. moderate to severe diarrhea (≥9 points); MAL-ED dichotomized as non-severe (<6 points) vs. severe diarrhea (≥6 points)

Alt text: Bar graph depicting the percentage of *Shigella*-attributable medically attended diarrhea classified as moderate or severe by each severity definition by age group (6-11 months, 12-23 months, and 24-25 months) and by culture positivity (culture positive, culture negative qPCR-attributable).

Table A4. Association between more severe diarrhea by dichotomized severity definitions and change in length/height-for-age z-score (ΔLAZ/HAZ) from enrollment to 3-month follow-up among medically-attended diarrhea (MAD) and *Shigella*-attributable MAD. Models among all diarrhea cases and stratified by guideline-recommended antibiotic treatment. All models adjusted for baseline LAZ/HAZ, site, and days from enrollment to 3-month follow-up visit.

	Total		**Guideline-recommended antibiotics**		**No guideline-recommended antibiotics**	
Severity definition[1]	**Mean difference (CI)**	**p-value**	**Mean difference (CI)**	**p-value**	**Mean difference (CI)**	**p-value**
All MAD	**N = 8767**		**N = 3211**		**N = 5556**	
GEMS MSD (moderate-to-severe)[2]	0.00 (-0.02, 0.02)	0.855	-0.02 (-0.06, 0.01)	0.152	-0.02 (-0.05, 0.01)	0.165
MVS (moderate or severe)[3]	-0.07 (-0.09, -0.05)	0.000	-0.05 (-0.08, -0.03)	0.000	-0.08 (-0.11, -0.06)	0.000
MVS (moderate or severe) and/or dysentery[4]	-0.05 (-0.07, -0.03)	0.000	-0.05 (-0.08, -0.02)	0.001	-0.07 (-0.10, -0.05)	0.000
Clark score (moderate to severe)[5]	-0.06 (-0.08, -0.04)	0.000	-0.06 (-0.09, -0.03)	0.000	-0.07 (-0.09, -0.04)	0.000
MAL-ED score (severe)[6]	-0.05 (-0.06, -0.03)	0.000	-0.05 (-0.07, -0.02)	0.001	-0.06 (-0.08, -0.03)	0.000
Shigella mortality score (moderate or severe)[7]	-0.04 (-0.07, -0.01)	0.013	-0.07 (-0.12, -0.03)	0.001	-0.02 (-0.06, 0.02)	0.286
***Shigella*-attributable MAD**	**N = 1832**		**N = 984**		**N = 848**	
GEMS MSD (moderate-to-severe)[2]	-0.01 (-0.05, 0.02)	0.471	-0.05 (-0.10, 0.00)	0.054	-0.04 (-0.10, 0.02)	0.208
MVS (moderate or severe)[3]	-0.07 (-0.10, -0.03)	0.000	-0.04 (-0.09, 0.01)	0.100	-0.10 (-0.15, -0.04)	0.000
MVS (moderate or severe) and/or dysentery[4]	-0.05 (-0.09, -0.02)	0.002	-0.07 (-0.12, -0.02)	0.009	-0.10 (-0.15, -0.05)	0.000
Clark score (moderate to severe)[5]	-0.03 (-0.07, 0.01)	0.160	-0.03 (-0.08, 0.02)	0.271	-0.03 (-0.10, 0.03)	0.319
MAL-ED score (severe)[6]	-0.04 (-0.07, 0.00)	0.025	-0.04 (-0.08, 0.01)	0.121	-0.05 (-0.10, 0.00)	0.048
Shigella mortality score (moderate or severe)[7]	-0.01 (-0.07, 0.05)	0.731	-0.03 (-0.10, 0.05)	0.485	0.00 (-0.10, 0.10)	0.960

CI: 95% confidence interval, GEMS: Global Enteric Multicenter Study, HAZ: Height-for-age z-score, LAZ: Length-for-age z-score, MAL-ED: Malnutrition and Enteric Disease Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score, QIC: quasi information Criterion, WHO: World Health Organization.

[1] Models adjusted for baseline LAZ/HAZ, site, and number of days from enrollment to 3-month follow-up visit.

[2] Defined as in Kotloff, Lancet GH, 2019. Moderate-to-severe diarrhea (MSD) defined as presenting to a health facility with diarrhea and severe or some dehydration (by WHO criteria), visible blood in stool, or inpatient admission.

[3] Defined in PATH Vesikaro Clinical Severity Scoring System Manual as a MVS of 9+.

[4] Defined as in Pavlinac, Vaccines, 2022 as a MVS of 9+ or presence of visible blood in stool.

[5] Defined as in Clark, JID, 1988 as a score of 9+.

[6] Defined as in Lee, J Pediatr Gastroenterol Nutr., 2016 as a score of 6+.

[7] Defined as in Pavlinac, CID, 2021 as a score of 6+.

Table A5. Diagnostic accuracy of dichotomized severity scores in identifying hospitalization and/or mortality within 14 days of enrollment among medically-attended diarrhea (MAD) and *Shigella*-attributable MAD. Calculated among all diarrhea cases and stratified by guideline-recommended antibiotic treatment.

	Total					Guideline-recommended antibiotics					No guideline-recommended antibiotics				
Severity definition	**Sensitivity (CI)**	**Specificity (CI)**	**Total accuracy (CI)**	**PPV (CI)**	**NPV (CI)**	**Sensitivity (CI)**	**Specificity (CI)**	**Total accuracy (CI)**	**PPV (CI)**	**NPV (CI)**	**Sensitivity (CI)**	**Specificity (CI)**	**Total accuracy (CI)**	**PPV (CI)**	**NPV (CI)**
All MAD			**N = 9476**					**N = 3366**					**N = 6110**		
GEMS MSD (moderate-to-severe)[1]	94.2 (91.1, 96.9)	66.5 (65.6, 67.4)	67.2 (66.4, 68.1)	6.8 (6, 7.7)	99.8 (99.7, 99.9)	97.9 (95.6, 100)	61.3 (59.8, 62.8)	62.9 (61.4, 64.4)	10.3 (8.7, 11.9)	99.8 (99.7, 100)	88.3 (81.7, 94.3)	69.3 (68.4, 70.3)	69.6 (68.7, 70.6)	4.3 (3.4, 5.2)	99.7 (99.6, 99.9)
MVS (moderate or severe)[2]	88.3 (84.2, 92.4)	60.1 (59.2, 61.1)	60.8 (59.9, 61.8)	5.4 (4.7, 6.2)	99.5 (99.3, 99.7)	88.4 (83.3, 93.4)	60.1 (58.4, 61.8)	61.3 (59.7, 63)	9.1 (7.8, 10.8)	99.1 (98.7, 99.5)	88.3 (81.3, 94.2)	60.1 (58.9, 61.3)	60.5 (59.3, 61.7)	3.3 (2.6, 4.1)	99.7 (99.5, 99.9)
MVS (moderate or severe) and/or dysentery[3]	89.6 (85.9, 93.2)	52.7 (51.7, 53.7)	53.7 (52.7, 54.6)	4.7 (4.1, 5.3)	99.5 (99.3, 99.7)	89.7 (84.7, 94.4)	44.3 (42.8, 45.8)	46.3 (44.8, 47.8)	6.8 (5.7, 7.9)	99 (98.4, 99.4)	89.4 (82.5, 95.1)	57.2 (56.1, 58.4)	57.7 (56.6, 58.9)	3.2 (2.5, 3.8)	99.7 (99.5, 99.9)
Clark score (moderate to severe)[4]	70.8 (65.5, 76.3)	76.6 (75.7, 77.4)	76.4 (75.6, 77.3)	7.3 (6.3, 8.3)	99 (98.8, 99.2)	74.7 (67.5, 81.4)	71.7 (70.2, 73.2)	71.8 (70.4, 73.3)	10.7 (8.8, 12.5)	98.4 (97.9, 98.9)	64.9 (55.7, 74.2)	79.2 (78.2, 80.2)	79 (78, 80)	4.7 (3.6, 5.8)	99.3 (99.1, 99.5)
MAL-ED score[5]	90 (86.1, 93.7)	49.1 (48.1, 50.1)	50.2 (49.2, 51.1)	4.4 (3.8, 5)	99.5 (99.3, 99.7)	91.1 (85.9, 95.2)	47 (45.2, 48.8)	49 (47.2, 50.7)	7.2 (6, 8.5)	99.1 (98.6, 99.5)	88.3 (81.8, 94.4)	50.2 (49, 51.4)	50.8 (49.6, 52)	2.7 (2.2, 3.2)	99.6 (99.4, 99.8)
Shigella mortality score (moderate or severe)[6]	72.9 (67, 78.8)	89.6 (89, 90.2)	89.2 (88.6, 89.8)	15.4 (13.2, 17.7)	99.2 (99, 99.4)	77.4 (70.3, 84.2)	91.7 (90.8, 92.6)	91.1 (90.2, 92)	29.7 (25.4, 34.5)	98.9 (98.5, 99.2)	66 (56.3, 76)	88.5 (87.7, 89.2)	88.1 (87.4, 88.9)	8.2 (6.5, 10.1)	99.4 (99.2, 99.6)
***Shigella*-attributable MAD**			**N = 1968**					**N = 1040**					**N = 928**		
GEMS MSD (moderate-to-severe)[1]	93.6 (85.4, 100)	56 (53.8, 58)	56.9 (54.8, 58.8)	4.9 (3.6, 6.4)	99.7 (99.4, 100)	94.4 (86.1, 100)	45.8 (42.9, 48.5)	47.5 (44.6, 50.1)	5.9 (4.1, 7.7)	99.6 (98.9, 100)	90.9 (66.7, 100)	67.1 (64.6, 69.6)	67.3 (65, 69.8)	3.2 (1.5, 5.2)	99.8 (99.5, 100)
MVS (moderate or severe)[2]	80.9 (69.7, 91.7)	63.1 (61, 65)	63.5 (61.5, 65.5)	5.1 (3.6, 6.6)	99.3 (98.8, 99.7)	83.3 (70, 94.4)	64.1 (61.4, 67.1)	64.8 (62.2, 67.6)	7.7 (5.1, 10.4)	99.1 (98.3, 99.7)	72.7 (40, 100)	61.9 (58.9, 64.8)	62.1 (59.1, 65)	2.2 (0.8, 3.8)	99.5 (98.8, 100)
MVS (moderate or severe) and/or dysentery[3]	85.1 (74.3, 94.5)	46.4 (44.1, 48.7)	47.4 (45.2, 49.6)	3.7 (2.7, 4.9)	99.2 (98.6, 99.8)	88.9 (78, 97.6)	37.1 (34.3, 39.7)	38.8 (36.2, 41.6)	4.8 (3.3, 6.4)	98.9 (97.9, 99.8)	72.7 (44.4, 100)	56.7 (53.6, 59.8)	56.9 (53.8, 60)	2 (0.7, 3.4)	99.4 (98.8, 100)
Clark score (moderate to severe)[4]	66 (52.6, 79.4)	75.3 (73.4, 77.1)	75.1 (73.1, 77)	6.1 (4.2, 8.1)	98.9 (98.3, 99.4)	72.2 (57.1, 86.7)	72 (69.4, 74.7)	72 (69.3, 74.7)	8.5 (5.5, 11.6)	98.6 (97.8, 99.4)	45.5 (16.7, 80)	78.8 (76.2, 81.4)	78.4 (75.7, 81)	2.5 (0.5, 5)	99.2 (98.5, 99.7)
MAL-ED score[5]	87.2 (77.8, 95.7)	47.3 (45.1, 49.2)	48.2 (46, 50.2)	3.9 (2.8, 5)	99.3 (98.8, 99.8)	86.1 (73.3, 97.2)	45.3 (42.3, 48)	46.7 (43.8, 49.4)	5.3 (3.5, 7.1)	98.9 (97.8, 99.8)	90.9 (66.7, 100)	49.4 (46.3, 52.5)	49.9 (46.8, 53)	2.1 (0.9, 3.4)	99.8 (99.3, 100)
Shigella mortality score (moderate or severe)[6]	66 (51.2, 79)	88.5 (87.3, 89.7)	88 (86.7, 89.2)	12.3 (8.6, 16.4)	99.1 (98.5, 99.5)	63.9 (47.7, 80)	89.3 (87.6, 90.8)	88.5 (86.7, 90)	17.7 (11.6, 23.9)	98.6 (97.7, 99.3)	72.7 (45.4, 100)	87.6 (85.8, 89.4)	87.4 (85.5, 89.3)	6.6 (2.8, 10.9)	99.6 (99.1, 100)

CI: 95% confidence interval, GEMS: Global Enteric Multicenter Study, HAZ: Height-for-age z-score, LAZ: Length-for-age z-score, MAL-ED: Malnutrition and Enteric Disease Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score, WHO: World Health Organization.

[1] Defined as in Kotloff, Lancet GH, 2019. Moderate-to-severe diarrhea (MSD) defined as presenting to a health facility with diarrhea and severe or some dehydration (by WHO criteria), visible blood in stool, or inpatient admission.

[2] Defined as in PATH Vesikari Clinical Severity Scoring System Manual as a MVS of 9+.

[3] Defined as in Pavlinac, Vaccines, 2022 as a MVS of 9+ or presence of visible blood in stool.

[4] Defined as in Clark, JID, 1988 as a score of 9+.

[5] Defined as in Lee, J Pediatr Gastroenterol Nutr., 2016 as a score of 6+.

[6] Defined as in Pavlinac, CID, 2021 as a score of 6+.



Figure A3. Receiver operating characteristic (ROC) curves of four continuous severity scores with the dehydration and hospitalization components removed, respectively, on the outcome of mortality or hospitalization within 14 days of enrollment among children with *Shigella*-attributable medically-attended diarrhea. Shaded bands represent 95% confidence intervals. Plotted points represent sensitivity and specificity of threshold used for dichotomizing four continuous scores, as well as sensitivity and specificity of two non-numeric severity definitions.

GEMS: Global Enteric Multicenter Study, MSD: moderate-to-severe diarrhea, MVS: modified Vesikari score
Scores dichotomized as follows: MVS dichotomized as mild (<9 points) vs. moderate or severe (≥9 points); MVS +/- dysentery dichotomized as mild with no dysentery vs. moderate/severe or dysentery; GEMS MSD dichotomized as less-severe-diarrhea vs. moderate-to-severe-diarrhea; *Shigella* mortality score dichotomized as mild (<6 points) vs. moderate or severe (≥6 points) diarrhea; Clark score dichotomized as mild (<9 points) vs. moderate to severe diarrhea (≥9 points); MAL-ED dichotomized as non-severe (<6 points) vs. severe diarrhea (≥6 points)

Alt text: Two receiver operating characteristic curves of four continuous severity scores on hospitalization or mortality within 14 days of enrollment among children with *Shigella*-attributable medically-attended diarrhea. In the left plot the hospitalization component has been removed from the scores, and *Shigella* mortality score has lower area under the curve compared to the other three scores (MVS, Clark score, and MAL-ED score), which perform similarly. In the right plot the dehydration component has been removed from the scores and Shigella mortality score has a higher area under the curve than the other scores, which perform similarly.